Safety of Alogliptin as Add on Therapy with Metformin among Inadequately Control Type 2 Diabetes Mellitus Patients Attending Rajshahi Diabetic Association General Hospital

Background: Globally, diabetes mellitus is a leading cause of morbidity and mortality. Even though oral antidiabetic medications improve glycaemic control, they do not address all of the glucoregulatory mechanisms impacted by diabetes and long-term maintenance of appropriate blood glucose control can be challenging, especially with monotherapy. Although safety is debatable, Alogliptin has recently been used in combination therapies. Methods: This quasi-experimental study was carried out on Type 2 DM patients who had insufficient glycaemic control with Metformin and diet with lifestyle modification therapy at the Department of Pharmacology and Therapeutics, Rajshahi Medical College, Rajshahi in cooperation with Rajshahi Diabetic Association General Hospital (RADAS), Rajshahi. 42 Type 2 DM patients of both sexes were enrolled in the study based on predetermined eligibility criteria. Following breakfast, each patient received a once-daily dose of tablet Alogliptin 25 mg in addition to the ongoing treatment of tablet Metformin 1000 mg. The patients were monitored at the conclusion of four, eight, and twelve weeks of medication administration. Results: The mean systolic and diastolic blood pressures were 125.84 and 80.35 mmHg respectively at baseline which reduced to 123.23 and 79.84 mmHg after 12 weeks of intervention but these reductions were statistically non-significant (p > 0.05 for both SBP and DBP). The body weight and BMI did not significantly change during the 12 weeks period of intervention (p > 0.05 and p > 0.05, respectively). There was no statistically significant difference in headache, nausea, vomiting, diarrhoea, abdominal pain, appetite change, serum creatinine and SGPT between baseline and after 12 weeks of drug administration (p > 0.05 for each case). Conclusions: So, combination of Alogliptin with metformin are safe as like as Metformin alone.